EUVIMEDEUVIMED entdecken
Crossref

Radiofrequency Ablation as a Possible Treatment Option for Marine-Lenhart Syndrome

Shahzad Ahmad, Zeeshan Irfan, Rohit Singh

VideoEndocrinology™ · 2026-01 · 13

DOI: 10.1177/23299738261457883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift VideoEndocrinology™, online erschienen am 16.07.2026. Verfasst von Shahzad Ahmad und 2 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The coexistence of autonomously functioning thyroid nodules (AFTNs) and Graves’ disease is referred to as Marine-Lenhart Syndrome (MLS). Estimated to occur in 0.8–4.1% of patients with Graves’. 1 – 4 MLS and AFTNs are diagnosed using a combination of. • Serum thyroid-stimulating immunoglobulin (TSI) and thyroid hormone receptor antibody levels. 5 Scintigraphy with radioiodine thyroid uptake studies. 4 , 5 Radioiodine ablation (I-131) and surgery are considered definitive therapies 4 but carry risk of iatrogenic hypothyroidism. A recent prospective 2-year study evaluating the use of radiofrequency ablation (RFA) for small toxic goiters and Graves’ disease demonstrated excellent efficacy 6 The safety and efficacy of RFA for AFTNs is well-established. 7 We describe the first reported case of MLS successfully treated with RFA. Case Description: A 67-year-old Caucasian female with palpitations, nervousness, and shakiness. Examination revealed. Irregular, firm goiter Left-sided thyroid nodule Lid lag, lid retraction Mild exophthalmos Laboratory Findings. TSH: 0.01 IU/L (normal: 0.5–4.7 IU/mL) – suppressed Free T4: 2.7 μg/dL (normal: 0.8–1.7 μg/dL) – elevated Ultrasound. Showed a 1.4 cc left nodule in the setting of a hyperemic gland Radioactive Iodine Uptake and I-123 Scan Twenty-four-hour uptake: 32.7% Homogeneous uptake in the gland with focal increased uptake in the left-sided nodule Findings consistent with (MLS). TSI: 4.9 IU/L (reference < 0.54 IU/L) TRAb: 6.8 IU/L (reference 0.0–1.7 IU/L) Methimazole poorly tolerated I-131 versus surgery was offered but declined Patient opted for RFA Procedure: pericapsular local anesthesia (2% lidocaine) An 18-gauge internally cooled electrode (Cambridge Interventional, Burlington, MA) used with a 0.7 cm active Critical structures identified and avoided Vocal cord mobility monitored via ultrasound Moving-shot technique used Ablation of left toxic nodule followed by treating the surrounding thyroid The procedure was repeated on the right lobe, 20 watts power applied Ablation time: 14 minutes Vocal cords were re-evaluated post-procedure and found to be mobile Patient advised to discontinue methimazole post-procedure Results: Three months post-RFA Complete resolution of hyperthyroid symptoms TSH: 3.0 μIU/mL (normal) Six months post-RFA. TSH: 3.3 μIU/mL Free T4: 1.1 ng/mL Left AFTN: 0.2 cc (85.7% volume reduction) Left lobe volume: 2.5 cc (37.5% volume reduction) Right lobe volume: 1.7 cc (51.4% volume reduction) One year post RFA. TSH: 5 uIU/mL. Free T4: 1.2 ng/mL. TRAB titer negative.

Discussion

MLS is a unique form of thyrotoxicosis with no clearly established treatment protocol. Patients are typically managed with I-131 or surgery, which carries the risk of permanent hypothyroidism. This case represents the first reported instance of successful RFA treatment in a patient with MLS. RFA is already recognized as a safe and effective option for AFTN 7 and is showing promise as a treatment for selected cases of Graves’ disease 6 This case highlights the potential role of RFA in MLS, While Fung et al. 6 didn’t follow TRAB levels , in this patient titer Normalization might suggest spontaneous remission, or the possibility that RFA may normalize TRAb levels by reducing the antigenic load and altering the inflammatory microenvironment. Authors would like to thank Mr. Anuj Kumar for his help. Author(s) have received and archived patient consent for video recording/publication in advance of the video recording of the procedure. Authors affirm absence of COI/no financial disclosures to report. Running Time: 7 minutes and 7 seconds.

Zitieren

APA

Ahmad, S., Irfan, Z., & Singh, R. (2026). Radiofrequency Ablation as a Possible Treatment Option for Marine-Lenhart Syndrome. VideoEndocrinology™, 13. https://doi.org/10.1177/23299738261457883

Vancouver

Ahmad S, Irfan Z, Singh R. Radiofrequency Ablation as a Possible Treatment Option for Marine-Lenhart Syndrome. VideoEndocrinology™. 2026;13. doi:10.1177/23299738261457883

BibTeX
@article{Ahmad2026,
  author = {Ahmad, Shahzad and Irfan, Zeeshan and Singh, Rohit},
  title = {Radiofrequency Ablation as a Possible Treatment Option for Marine-Lenhart Syndrome},
  journal = {VideoEndocrinology™},
  year = {2026},
  volume = {13},
  doi = {10.1177/23299738261457883}
}
Kostenlos starten →